Ravi Shrivastava, Swity Deshmukh
Journal of Cancer Research and Treatment. 2013, 1(1), 4-11DOI:
Abstract: Mucositis is a consequence of cytostatic effects of anticancer therapy on the fast growing oral mucosal cells. The size of the ulcer increases due to subsequent bacterial and fungal growth, while the leakage of circulating toxins through damaged capillaries surrounding the ulcers causes severe irritation and burning sensation. Proteolytic enzymes, which are known to destroy cellular matrix, inhibit cell regeneration and healing. We tested OROSOL®, an osmotically active hypertonic solution containing specific protease-inhibiting plant procyanidins capable of cleaning the injury, removing the contaminants and stimulating cell growth as a new multiple therapeutic approach for the treatment of mucositis. Out of 69 total patients, 48 were treated with OROSOL® spray, 4-5 times per day for a period of 28 days. 21 patients in the classical treatment group used standard treatments. The grade of overall mucositis, intensity of pain and burning sensation, formation of new ulcers and effect on eating impairment were evaluated before treatment, 30 minutes after first product application and on days 1, 2, 3, 4, 7, 14, 21 and 28. Data were analyzed using SAS 9.1.3. Statistical program. Compared to the classical treatments group, Orosol® group showed significantly higher improvement in pain, burning sensation, eating abilities, grade of infection and overall mucositis. New ulcer formation rate was not affected. Mucositis treatment requires a multiple therapeutic approach of simultaneously eliminating the contaminants and the toxic chemicals from the ulcer as well as creating a favorable ground for healthy cell growth. OROSOL® seems highly effective in achieving these objectives.